News | November 10, 2022
Lupin Q2 FY2023 revenue remains flat
Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.
Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.
We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
Lutio has the potential to offer significant cost savings when available to UK patients.
New deal strengthens Congenica’s presence in India
Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.
Lupin is the 6th largest company in the Indian Pharmaceutical Market
Strive to empower public health with disinfection robotics solutions in post-pandemic era
BVX-0922 to target colorectal cancer under investigator-sponsored IND
This announcement comes after the formation of a new Intercontinental Region within GE Healthcare, led by Chaillot
State-of-the-art laboratory to support ingredient and specialty chemical innovation, product formulation application development and more sustainable solutions across Europe and beyond
Subscribe To Our Newsletter & Stay Updated
